Macroaxis LLC on LinkedIn: #stocks #stocktwits #thematic_portfolio (2024)

$LPTX - Upcoming quarterly report will be on 22nd of March 2024.: About 33.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Leap Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.75. The entity recorded a loss per share of 4.83. The firm had not issued any dividends in recent years. Leap Therapeutics had 1:10 split on the 21st of June 2023. https://lnkd.in/gKPhX_cg #stocks #stocktwits #thematic_portfolio

$VTGN - Next financial report expected on 26th of June 2024.: About 63.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.01. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 2.96. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. https://lnkd.in/gQ6_iaf4 #stocks #stocktwits #thematic_portfolio

$SCNI - Do not drop your Scinai Immunotherapeuti shares yet. Upcoming quarterly report is on 15th of April 2024: About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.59. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Scinai Immunotherapeutics recorded a loss per share of 4.36. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 25th of November 2022. https://lnkd.in/gH-FhHQK #stocks #stocktwits #thematic_portfolio

$ALRN - Should I trust the management in February 2024? Upcoming quarterly report is scheduled for 18th of March 2024.: About 25.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aileron Therapeutics recorded a loss per share of 2.85. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 11th of November 2022. https://lnkd.in/gC5y4MgX #stocks #stocktwits #thematic_portfolio

$MOLA - 15 for 1 Split can cause some disturbance for MOLECULIN BIOTECH: About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MOLECULIN BIOTECH recorded a loss per share of 1.31. The entity had not issued any dividends in recent years. The firm had 15:1 split on the 2nd of January 2024. https://lnkd.in/gZ23-XGb #stocks #stocktwits #thematic_portfolio

There’s New Hope for the IPO MarketAt least five hedge funds have benefited from two biopharma stocks that went public in February and are currently doing well.A pair of IPOs this month is generating some cautious optimism that the new-issues market may have finally emerged from its bear market slumber.Read the article below for more details.#ipo #sec #hope #gobeyond #biopharma #stocks #rally #capitalmarkets #gobig #pcaob #audit #readiness Grant Thornton LLP (US)

26

2 Comments

Organon ( $OGN ) current daily volatility is 3.29%, with beta of 2.78 and alpha of 0.03 over NYSE Composite: The company has 8.91B in debt. Organon retains ebitda of 1.53b. Organon is selling for under 16.83. That is 2.75 percent increase. Started trading at 16.38. https://lnkd.in/eppaycqF #hotstocks #investing #trading

#TH - Theratechnologies Announces 1for4 Reverse Stock Split - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements This news release constitutes a “designated news release” fo... July 20, 2023 at 07:00AM #StockMarket #MWN

$NHWK - Is Nighthawk Biosciences a good short-term buy? Upcoming quarterly report is scheduled for 29th of March 2024.: The company has price-to-book ratio of 0.27. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nighthawk Biosciences recorded a loss per share of 2.05. The entity last dividend was issued on the 11th of December 2020. The firm had 1:7 split on the 11th of December 2020. #stocks #stocktwits #thematic_portfolio

$ADXN - Next financial report will be announced on 9th of May 2024.: About 18.0% of the company shares are held by institutions such as insurance companies. The book value of Addex Therapeutics was presently reported as 0.05. The company recorded a loss per share of 20.01. Addex Therapeutics had not issued any dividends in recent years. The entity had 1:20 split on the 23rd of October 2023. #stocks #stocktwits #thematic_portfolio